Pierre Laurin Sells 82,738 Shares of ProMetic Life Sciences Inc. (PLI) Stock

ProMetic Life Sciences Inc. (TSE:PLI) Director Pierre Laurin sold 82,738 shares of the stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of C$1.44, for a total value of C$119,142.72.

Pierre Laurin also recently made the following trade(s):

  • On Tuesday, September 12th, Pierre Laurin sold 82,738 shares of ProMetic Life Sciences stock. The stock was sold at an average price of C$1.45, for a total value of C$119,970.10.
  • On Thursday, September 7th, Pierre Laurin sold 41,427 shares of ProMetic Life Sciences stock. The stock was sold at an average price of C$1.45, for a total value of C$60,069.15.

ProMetic Life Sciences Inc. (PLI) traded down 1.38% during trading on Friday, hitting $1.43. 2,102,143 shares of the stock were exchanged. The stock has a 50 day moving average of $1.43 and a 200-day moving average of $1.88. ProMetic Life Sciences Inc. has a 52 week low of $1.12 and a 52 week high of $3.24. The stock’s market cap is $1.01 billion.

TRADEMARK VIOLATION NOTICE: This report was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.chaffeybreeze.com/2017/09/15/pierre-laurin-sells-82738-shares-of-prometic-life-sciences-inc-pli-stock.html.

PLI has been the subject of a number of recent analyst reports. National Bank Financial increased their price target on ProMetic Life Sciences from C$2.00 to C$2.50 in a report on Wednesday, August 30th. Scotiabank decreased their price target on ProMetic Life Sciences from C$4.75 to C$4.00 and set an “outperform” rating for the company in a report on Friday, July 7th. Canaccord Genuity decreased their price target on ProMetic Life Sciences from C$4.75 to C$4.50 and set a “buy” rating for the company in a report on Monday, June 19th. Royal Bank Of Canada reiterated an “outperform” rating on shares of ProMetic Life Sciences in a report on Wednesday, May 24th. Finally, TD Securities decreased their price target on ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating for the company in a report on Wednesday, August 16th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of C$3.60.

About ProMetic Life Sciences

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Insider Buying and Selling by Quarter for ProMetic Life Sciences (TSE:PLI)

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply